Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Andrew Haydon"'
Autor:
Prachi Bhave, Andrew Haydon
Publikováno v:
Australasian Journal of Dermatology. 61:203-209
Stage III melanoma involves regional lymph nodes and/or in-transit or satellite disease, without spread to distant metastatic sites. Stage IIIA melanoma includes a T1a-T2a primary lesion with N1a or N2a nodal involvement, whilst stage IIID melanoma i
Autor:
Vanna Chiarion-Sileni, James Larkin, Richard F. Kefford, John M. Kirkwood, Mario Mandalà, Stephanie Manson, Kohinoor Dasgupta, Victoria Atkinson, Thierry Lesimple, Marta Nyakas, Reinhard Dummer, Axel Hauschild, Andrew Haydon, Laurent Mortier, Georgina V. Long, Dirk Schadendorf, Caroline Robert, Bijoyesh Mookerjee, Mario Santinami, Ruth Plummer, Caroline Dutriaux, Jacob Schachter, Roy Koruth
Publikováno v:
The Lancet Oncology. 20:701-710
Summary Background In the phase 3 COMBI-AD study, patients with resected, stage III melanoma with BRAF V600E or BRAF V600K mutations received adjuvant dabrafenib plus trametinib or placebo. The primary analysis showed that dabrafenib plus trametinib
Autor:
Dirk Schadendorf, Caroline Dutriaux, Caroline Robert, Reinhard Dummer, John M. Kirkwood, Marta Nyakas, Mario Mandalà, Laurent Mortier, Axel Hauschild, Kohinoor Dasgupta, Monique Tan, Eduard Gasal, James Larkin, Jacob Schachter, Vanna Chiarion Sileni, Andrew Haydon, Victoria Atkinson, Mario Santinami, Georgina V. Long
10001 Background: Previous results of the COMBI-AD trial (NCT01682083) showed a significant relapse-free survival (RFS) benefit with 12 mo of adjuvant D+T vs placebo (PBO) in pts with high-risk resected stage III BRAF V600E/K–mutant melanoma. In th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f486f97df79593e3e9abb490624153c0
Autor:
Vanna Chiarion-Sileni, M. Mandal, A. Hauschild, Bijoyesh Mookerjee, R. Ji, Jeffrey J. Legos, John M. Kirkwood, Victoria Atkinson, Jacob Schachter, James Larkin, Richard F. Kefford, Ping Zhang, Caroline Robert, Caroline Dutriaux, M. Santinami, Andrew Haydon, Dirk Schadendorf, Georgina V. Long, Thierry Lesimple, Reinhard Dummer, Laurent Mortier, Marta Nyakas, Ruth Plummer
Publikováno v:
New England Journal of Medicine. 377:1813-1823
Combination therapy with the BRAF inhibitor dabrafenib plus the MEK inhibitor trametinib improved survival in patients with advanced melanoma with BRAF V600 mutations. We sought to determine whether adjuvant dabrafenib plus trametinib would improve o
Autor:
John M. Kirkwood, Mario Santinami, Tomas Haas, C. Robert, J.M.G. Larkin, Monique Tan, C. Dutriaux, Dirk Schadendorf, Laurent Mortier, Georgina V. Long, Jacob Schachter, Mike Lau, Axel Hauschild, Hiya Banerjee, Andrew Haydon, Reinhard Dummer, Victoria Atkinson, Mario Mandalà, Marta Nyakas, V. Chiarion Sileni
Publikováno v:
Annals of Oncology. 31:S743-S744
Autor:
Jacob Schachter, Dirk Schadendorf, Eduard Gasal, Laurent Mortier, Marta Nyakas, Egbert de Jong, Caroline Dutriaux, Reinhard Dummer, Mario Santinami, Georgina V. Long, John M. Kirkwood, Mario Mandalà, Victoria Atkinson, Vanna Chiarion-Sileni, Andrew Haydon, Caroline Robert, Christine-Elke Ortmann, James Larkin, Richard F. Kefford, Axel Hauschild
9582 Background: In the COMBI-AD trial (NCT01682083), 12 mo of adjuvant D+T led to significant improvement of RFS vs PBO (hazard ratio [HR], 0.47; P < .001) in pts with resected BRAF V600–mutant stage III melanoma; 3- and 4-year RFS rates were 59%
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f42511b4b46cd8c4fde9d100d74a0872
Autor:
John M. Kirkwood, James Larkin, Mario Mandalà, Richard F. Kefford, Tomas Haas, Vanna Chiarion-Sileni, Caroline Robert, Kohinoor Dasgupta, Axel Hauschild, Mario Santinami, Mark Shilkrut, Caroline Dutriaux, Eduard Gasal, Dirk Schadendorf, Georgina V. Long, Jacob Schachter, Andrew Haydon, Laurent Mortier, Ruth Plummer, Victoria Atkinson, Marta Nyakas, Thierry Lesimple, Reinhard Dummer
Publikováno v:
Journal of Clinical Oncology
J Clin Oncol
J Clin Oncol
Purpose Dabrafenib plus trametinib improved relapse-free survival (RFS) versus placebo (hazard ratio [HR], 0.47; P < .001) in patients with resected BRAF V600–mutant stage III melanoma (BRF115532; COMBI-AD; ClinicalTrials.gov identifier: NCT0168208
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00393631f41ac7c8491c0de2c7f007a8
https://doi.org/10.5167/uzh-158265
https://doi.org/10.5167/uzh-158265
Autor:
John M. Kirkwood, Monique Tan, Caroline Dutriaux, James E. Larkin, Dirk Schadendorf, Vanna Chiarion Sileni, Reinhard Dummer, Laurent Mortier, Georgina V. Long, Andrew Haydon, Mario Santinami, Mike Lau, Jacob Schachter, Caroline Robert, Axel Hauschild, Victoria Atkinson, Tomas Haas, Hiya Banerjee, Mario Mandalà, Marta Nyakas
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 5:s2
not available.
Autor:
Andrew Haydon, Marta Nyakas, James Larkin, Richard F. Kefford, Reinhard Dummer, Egbert de Jong, Dirk Schadendorf, V. Chiarion-Sileni, Caroline Robert, Christine-Elke Ortmann, John M. Kirkwood, Axel Hauschild, Victoria Atkinson, Mario Santinami, Caroline Dutriaux, Edward Gasal, Georgina V. Long, Mario Mandalà, Jacob Schachter, Laurent Mortier
Publikováno v:
SKIN The Journal of Cutaneous Medicine. 3:S53
not available.
Autor:
Victoria Atkinson, Andrew Haydon, Caroline Robert, John M. Kirkwood, Jan C. Brase, Mario Mandalà, Marta Nyakas, James Garrett, James Larkin, Richard F. Kefford, Caroline Dutriaux, Reinhard Dummer, Axel Hauschild, Catarina D. Campbell, Bijoyesh Mookerjee, Dirk Schadendorf, Vanna Chiarion-Sileni, Paola Aimone, Georgina V. Long, Mario Santinami
9574Background: In the COMBI-AD trial, adjuvant D + T resulted in a significant relapse-free survival benefit (HR, 0.47 [95% CI, 0.39-0.58]; P < .001) vs pbo in pts with resected stage III BRAF V60...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::92ad03e7f7c5e730efb55c2b885bece4